Verrica Pharmaceuticals Inc

Appointment of Interim Principal Financial Officer and Interim Principal Accounting Officer

On November 1, 2024, our Board of Directors designated Ted White, our President and Chief Executive Officer and a director of the Company, as the Company’s interim principal financial officer and interim principal accounting officer, effective immediately, to serve until November 5, 2024.

Information regarding Mr. White’s background and business experience is set forth under the caption “Class III Director Nominees for Election for a Three-Year Term Expiring at the 2027 Annual Meeting” in our definitive proxy statement filed with the Securities and Exchange Commission on April 19, 2024 and is incorporated herein by reference. There are no arrangements or understandings between Mr. White and any other persons pursuant to which he was selected as an officer or director of ours. There are also no family relationships between Mr. White and any of our director or executive officers, and Mr. White has no direct or indirect material interest in any related party transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

We did not enter into, or materially amend, any material plan, contract or arrangement to which Mr. White is a party or in which he participates in connection with Mr. White’s designation as interim principal financial officer and interim principal accounting officer, or make or modify any grant or award to Mr. White under any such plan, contract or arrangement.

Rule 10b5-1 Trading Arrangements and Non-Rule 10b5-1 Trading Arrangements

During the three months ended September 30, 2024, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted, modified orterminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408 of Regulation S-K).